BCL2 and Thrombocytopenia: Since current strategies focus on targeting pathways that promote cell survival, collateral damage to other cell types, as observed in the case of thrombocytopenia with the BCL‐2 family inhibitor ABT‐263 (Schoenwaelder et al., 2011), are a current target for improvement.